OXYMETAZOLINE HYDROCHLORIDE

OXYMETAZOLINE HYDROCHLORIDE was reported 5107 times

OXYMETAZOLINE HYDROCHLORIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 REBOUND NASAL CONGESTION 61 0.3486
1 PERITONEAL HAEMATOMA 4 0.0267
2 APPLICATION SITE HYPOAESTHESIA 5 0.0214
3 ANOSMIA 287 0.0198
4 PRODUCT CLOSURE REMOVAL DIFFICULT 20 0.0196
5 NASAL DISCOMFORT 152 0.0192
6 NASAL MUCOSAL DISORDER 10 0.0172
7 NASAL SEPTUM PERFORATION 11 0.0170
8 CALCIUM IONISED DECREASED 4 0.0165
9 APPLICATION SITE ACNE 8 0.0163
10 NASAL TURBINATE HYPERTROPHY 6 0.0159
11 SINONASAL OBSTRUCTION 5 0.0124
12 ROSACEA 54 0.0116
13 BURNING SENSATION MUCOSAL 4 0.0113
14 RHINALGIA 31 0.0113
15 NASAL OBSTRUCTION 21 0.0112
16 NASAL SEPTAL OPERATION 4 0.0110
17 CEREBRAL VASOCONSTRICTION 8 0.0108
18 NASAL DISORDER 27 0.0101
19 CAPILLARY FRAGILITY 5 0.0098
20 AMPHETAMINES POSITIVE 7 0.0093
21 NASAL OPERATION 6 0.0088
22 SINUS POLYP 5 0.0087
23 NASAL INFLAMMATION 9 0.0085
24 APPLICATION SITE PARAESTHESIA 11 0.0084
25 APPLICATION SITE WARMTH 10 0.0078
26 AGEUSIA 184 0.0074
27 EXPOSURE VIA DIRECT CONTACT 7 0.0074
28 HYPOSMIA 11 0.0073
29 NASAL SEPTUM DEVIATION 14 0.0072
30 DRUG DEPENDENCE 1141 0.0071
31 APPLICATION SITE DERMATITIS 6 0.0064
32 REBOUND EFFECT 69 0.0061
33 CEREBRAL ARTERY THROMBOSIS 3 0.0058
34 ENDOCRINE OPHTHALMOPATHY 5 0.0058
35 NASAL INJURY 4 0.0055
36 NASAL OEDEMA 10 0.0055
37 BLOOD PH INCREASED 3 0.0054
38 PRODUCT CLOSURE ISSUE 3 0.0054
39 SINUS OPERATION 12 0.0050
40 OBSTRUCTIVE SLEEP APNOEA SYNDROME 7 0.0048
41 INFUSION SITE MASS 5 0.0046
42 VASOCONSTRICTION 4 0.0046
43 CERUMEN IMPACTION 4 0.0044
44 PRODUCT CONTAINER ISSUE 36 0.0042
45 BRONCHIAL WALL THICKENING 3 0.0042
46 BACTERIAL DISEASE CARRIER 3 0.0041
47 INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION 3 0.0039
48 INCORRECT PRODUCT ADMINISTRATION DURATION 78 0.0036
49 HYPOGEUSIA 7 0.0036
50 SINUS HEADACHE 21 0.0035
51 TONGUE HAEMORRHAGE 4 0.0034
52 PRODUCT CONTAMINATION MICROBIAL 4 0.0034
53 CANDIDA SEPSIS 3 0.0033
54 APPLICATION SITE ERYTHEMA 84 0.0032
55 NASAL PRURITUS 4 0.0032
56 PRODUCT PACKAGE ASSOCIATED INJURY 7 0.0031
57 SINUS ARRHYTHMIA 4 0.0031
58 COLONIC POLYP 5 0.0030
59 APPLICATION SITE DRYNESS 10 0.0029
60 APPLICATION SITE INFLAMMATION 4 0.0029
61 APPLICATION SITE PAPULES 3 0.0028
62 DEVICE INFUSION ISSUE 7 0.0028
63 SINUS DISORDER 55 0.0028
64 KIDNEY ENLARGEMENT 3 0.0028
65 INCORRECT DRUG ADMINISTRATION DURATION 75 0.0027
66 NASAL CONGESTION 156 0.0027
67 APPLICATION SITE PAIN 58 0.0026
68 PNEUMONIA PSEUDOMONAL 4 0.0026
69 MEAN CELL VOLUME DECREASED 4 0.0026
70 PRODUCT ADMINISTRATION INTERRUPTED 20 0.0025
71 NASAL ULCER 4 0.0025
72 INFUSION SITE HAEMORRHAGE 8 0.0024
73 EDUCATIONAL PROBLEM 4 0.0024
74 NASAL DRYNESS 15 0.0024
75 PARANASAL SINUS DISCOMFORT 9 0.0024
76 CAROTID ARTERY DISEASE 3 0.0024
77 NOCTURNAL DYSPNOEA 3 0.0024
78 ACUTE SINUSITIS 4 0.0023
79 INFUSION SITE SWELLING 14 0.0022
80 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME 3 0.0022
81 EAR CONGESTION 6 0.0022
82 CLUSTER HEADACHE 3 0.0022
83 INFUSION SITE RASH 3 0.0022
84 ESSENTIAL HYPERTENSION 4 0.0022
85 SINUS PAIN 5 0.0021
86 PURULENCE 4 0.0021
87 SNEEZING 46 0.0020
88 MULTIPLE ALLERGIES 16 0.0020
89 PRECANCEROUS SKIN LESION 3 0.0020
90 SUFFOCATION FEELING 5 0.0020
91 PRODUCT PACKAGING DIFFICULT TO OPEN 5 0.0019
92 DILATATION VENTRICULAR 4 0.0019
93 EPISTAXIS 141 0.0019
94 CHRONIC SINUSITIS 7 0.0019
95 AORTIC VALVE DISEASE 3 0.0019
96 HYPERPHOSPHATAEMIA 4 0.0019
97 PROTEIN TOTAL DECREASED 7 0.0019
98 EXPIRED DRUG ADMINISTERED 9 0.0018
99 APPLICATION SITE SWELLING 9 0.0018
100 MEDICAL PROCEDURE 3 0.0018
101 GASTROINTESTINAL HYPOMOTILITY 4 0.0018
102 DRUG EFFECT DELAYED 8 0.0018
103 PRE-EXISTING CONDITION IMPROVED 11 0.0018
104 INFUSION SITE DISCHARGE 3 0.0017
105 INFUSION SITE PAIN 22 0.0017
106 UPPER-AIRWAY COUGH SYNDROME 14 0.0017
107 SEASONAL ALLERGY 24 0.0017
108 MITRAL VALVE DISEASE 3 0.0017
109 PUSTULE 4 0.0017
110 OXYGEN CONSUMPTION INCREASED 4 0.0017
111 INFUSION SITE ERYTHEMA 14 0.0017
112 ATELECTASIS 16 0.0017
113 LOBAR PNEUMONIA 3 0.0016
114 HYPERVOLAEMIA 8 0.0016
115 APPLICATION SITE RASH 22 0.0016
116 HYPERPARATHYROIDISM SECONDARY 4 0.0016
117 INFUSION SITE PRURITUS 5 0.0016
118 FACIAL PAIN 14 0.0016
119 CANCER PAIN 4 0.0016
120 VASCULAR DEVICE INFECTION 7 0.0015
121 DEAFNESS NEUROSENSORY 5 0.0015
122 MUCOSAL DRYNESS 3 0.0015
123 SKIN TIGHTNESS 7 0.0015
124 EAR HAEMORRHAGE 3 0.0015
125 SINUS CONGESTION 20 0.0015
126 DRY THROAT 15 0.0015
127 VIRAL UPPER RESPIRATORY TRACT INFECTION 7 0.0015
128 PAROSMIA 11 0.0015
129 RHINORRHOEA 93 0.0014
130 HANGOVER 5 0.0014
131 NEUROGENIC BLADDER 3 0.0014
132 BREATH SOUNDS ABNORMAL 7 0.0014
133 DRUG EFFECT DECREASED 76 0.0014
134 INFUSION SITE BRUISING 3 0.0014
135 UPPER RESPIRATORY TRACT CONGESTION 4 0.0014
136 PRODUCT LOT NUMBER ISSUE 3 0.0014
137 RHINITIS ALLERGIC 6 0.0013
138 COMPUTERISED TOMOGRAM ABNORMAL 3 0.0013
139 AUTOIMMUNE THYROIDITIS 5 0.0013
140 SNORING 5 0.0013
141 FACE INJURY 5 0.0013
142 PROSTATITIS 4 0.0013
143 NEPHROGENIC ANAEMIA 6 0.0013
144 PROSTATOMEGALY 5 0.0013
145 SLEEP APNOEA SYNDROME 24 0.0013
146 CUSHINGOID 4 0.0012
147 RHINITIS 10 0.0012
148 DERMATITIS CONTACT 14 0.0012
149 CARTILAGE INJURY 3 0.0012
150 APPLICATION SITE EXFOLIATION 5 0.0012
151 PRODUCT FORMULATION ISSUE 8 0.0012
152 SKIN INJURY 4 0.0012
153 PRODUCT USE COMPLAINT 19 0.0012
154 HEPATIC CYST 4 0.0012
155 HEPATOSPLENOMEGALY 3 0.0012
156 LEFT VENTRICULAR HYPERTROPHY 5 0.0012
157 AORTIC ARTERIOSCLEROSIS 3 0.0012
158 ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT 3 0.0012
159 SINUSITIS 119 0.0012
160 MUSCLE STRAIN 10 0.0012
161 TENDERNESS 12 0.0012
162 APPLICATION SITE PRURITUS 26 0.0011
163 DRUG ABUSER 7 0.0011
164 DRUG SCREEN POSITIVE 9 0.0011
165 PRODUCT CONTAMINATION 4 0.0011
166 DEPENDENCE 61 0.0011
167 MONOCYTE COUNT INCREASED 4 0.0011
168 PRODUCT USE ISSUE 204 0.0011
169 BURNING SENSATION 76 0.0011
170 WOUND HAEMORRHAGE 4 0.0011
171 INTERVERTEBRAL DISC DEGENERATION 10 0.0011
172 HYPERACUSIS 4 0.0011
173 LUNG CONSOLIDATION 3 0.0011
174 SKIN INFECTION 12 0.0011
175 SOMNAMBULISM 7 0.0011
176 LACRIMATION INCREASED 32 0.0011
177 CATHETER SITE INFECTION 4 0.0011
178 OXYGEN SATURATION ABNORMAL 3 0.0011
179 SUBCUTANEOUS ABSCESS 5 0.0010
180 RESPIRATORY TRACT CONGESTION 16 0.0010
181 INFUSION SITE REACTION 3 0.0010
182 HYPERPHAGIA 4 0.0010
183 EMERGENCY CARE 3 0.0010
184 DRUG TOLERANCE 5 0.0010
185 THERMAL BURN 7 0.0010
186 DIVERTICULUM 7 0.0010
187 DECUBITUS ULCER 8 0.0010
188 DUODENITIS 3 0.0010
189 BRAIN NATRIURETIC PEPTIDE INCREASED 3 0.0010
190 BENIGN PROSTATIC HYPERPLASIA 5 0.0010
191 APPLICATION SITE IRRITATION 12 0.0010
192 DRUG USE DISORDER 8 0.0010
193 ELECTROENCEPHALOGRAM ABNORMAL 3 0.0009
194 ORTHOPNOEA 3 0.0009
195 TENSION HEADACHE 4 0.0009
196 EAR PAIN 18 0.0009
197 APPLICATION SITE VESICLES 6 0.0009
198 HEPATIC LESION 4 0.0009
199 CHAPPED LIPS 4 0.0009
200 PHARYNGEAL SWELLING 9 0.0009
201 LYMPHOCYTE COUNT INCREASED 3 0.0009
202 HAEMORRHAGIC ANAEMIA 4 0.0009
203 WRONG DRUG ADMINISTERED 8 0.0009
204 FEELING JITTERY 17 0.0009
205 NEOPLASM RECURRENCE 3 0.0009
206 PERIORBITAL SWELLING 5 0.0009
207 BLOOD ALBUMIN DECREASED 7 0.0009
208 TRICUSPID VALVE INCOMPETENCE 7 0.0009
209 ABDOMINAL HERNIA 4 0.0009
210 EAR DISCOMFORT 9 0.0009
211 CHOKING 17 0.0009
212 RESPIRATION ABNORMAL 6 0.0009
213 ARTHRITIS INFECTIVE 4 0.0009
214 RALES 5 0.0009
215 CAROTID ARTERY STENOSIS 3 0.0009
216 PRODUCT LABEL CONFUSION 5 0.0009
217 HYPERTRIGLYCERIDAEMIA 5 0.0009
218 PRODUCT PACKAGING ISSUE 8 0.0008
219 POOR QUALITY SLEEP 18 0.0008
220 SUPRAVENTRICULAR TACHYCARDIA 8 0.0008
221 TOOTH INFECTION 11 0.0008
222 ALCOHOL USE 3 0.0008
223 NASAL POLYPS 4 0.0008
224 PHARYNGITIS 10 0.0008
225 SUNBURN 6 0.0008
226 MALNUTRITION 9 0.0008
227 UPPER RESPIRATORY TRACT INFECTION 37 0.0008
228 PHOTOPSIA 5 0.0008
229 RESPIRATORY RATE INCREASED 7 0.0008
230 FOREIGN BODY SENSATION IN EYES 5 0.0008
231 EXPIRED PRODUCT ADMINISTERED 26 0.0008
232 INCREASED UPPER AIRWAY SECRETION 4 0.0008
233 ROTATOR CUFF SYNDROME 10 0.0008
234 THROAT TIGHTNESS 21 0.0008
235 OROPHARYNGEAL DISCOMFORT 7 0.0008
236 MUSCLE RUPTURE 3 0.0008
237 EYE DISCHARGE 8 0.0008
238 END STAGE RENAL DISEASE 14 0.0008
239 BRAIN FOG 12 0.0008
240 PRODUCT ODOUR ABNORMAL 8 0.0008
241 PNEUMONIA FUNGAL 3 0.0008
242 PATENT DUCTUS ARTERIOSUS 3 0.0008
243 DYSGEUSIA 56 0.0008
244 CEREBRAL ATROPHY 3 0.0008
245 OBSTRUCTION 3 0.0008
246 INTRACRANIAL ANEURYSM 3 0.0007
247 INJECTION SITE DISCHARGE 4 0.0007
248 GINGIVITIS 4 0.0007
249 FOOT FRACTURE 14 0.0007
250 APPLICATION SITE DISCOLOURATION 3 0.0007
251 PERIPHERAL ISCHAEMIA 3 0.0007
252 PERIPHERAL VENOUS DISEASE 3 0.0007
253 IMPAIRED GASTRIC EMPTYING 10 0.0007
254 DRUG PRESCRIBING ERROR 14 0.0007
255 ECONOMIC PROBLEM 11 0.0007
256 JOINT EFFUSION 5 0.0007
257 DENTAL CARIES 8 0.0007
258 ACCIDENTAL EXPOSURE 3 0.0007
259 THROAT IRRITATION 32 0.0007
260 PRODUCTIVE COUGH 34 0.0007
261 MITRAL VALVE INCOMPETENCE 8 0.0007
262 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 50 0.0007
263 ALCOHOLISM 3 0.0007
264 ABNORMAL SENSATION IN EYE 3 0.0007
265 VISUAL DISTURBANCE 4 0.0007
266 EXERCISE TOLERANCE DECREASED 4 0.0007
267 CARDIAC MURMUR 6 0.0007
268 HORDEOLUM 3 0.0007
269 PANIC REACTION 5 0.0007
270 RESPIRATORY SYNCYTIAL VIRUS INFECTION 6 0.0007
271 FLUID OVERLOAD 10 0.0007
272 SLUGGISHNESS 7 0.0007
273 GROIN PAIN 6 0.0007
274 SPINAL OSTEOARTHRITIS 6 0.0007
275 CATHETERISATION CARDIAC 3 0.0007
276 INCONTINENCE 7 0.0007
277 PRESYNCOPE 16 0.0007
278 HAEMOGLOBIN INCREASED 3 0.0007
279 EAR DISORDER 3 0.0007
280 INSURANCE ISSUE 10 0.0007
281 PNEUMONIA BACTERIAL 6 0.0007
282 CHRONIC MYELOID LEUKAEMIA 3 0.0006
283 CONCUSSION 5 0.0006
284 APHONIA 9 0.0006
285 THINKING ABNORMAL 12 0.0006
286 EAR INFECTION 17 0.0006
287 SECRETION DISCHARGE 8 0.0006
288 MULTIPLE INJURIES 4 0.0006
289 TOOTH FRACTURE 7 0.0006
290 CARDIAC TAMPONADE 3 0.0006
291 RECALLED PRODUCT ADMINISTERED 6 0.0006
292 ORAL PAIN 14 0.0006
293 THERAPEUTIC RESPONSE UNEXPECTED 28 0.0006
294 HIATUS HERNIA 8 0.0006
295 ANGINA UNSTABLE 4 0.0006
296 RESPIRATORY TRACT INFECTION 16 0.0006
297 INCORRECT DOSAGE ADMINISTERED 3 0.0006
298 INTERNAL HAEMORRHAGE 7 0.0006
299 BODY TEMPERATURE DECREASED 6 0.0006
300 APPLICATION SITE BURN 3 0.0006
301 TOOTHACHE 11 0.0006
302 PULMONARY CONGESTION 8 0.0006
303 WALKING AID USER 4 0.0006
304 HAEMATOCRIT DECREASED 12 0.0006
305 HEPATIC ENZYME ABNORMAL 3 0.0006
306 SPLENOMEGALY 7 0.0006
307 ATRIAL SEPTAL DEFECT 5 0.0006
308 ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED 3 0.0006
309 BLOOD IRON DECREASED 7 0.0006
310 BACTERAEMIA 7 0.0006
311 PRODUCT LABEL ISSUE 4 0.0006
312 AMMONIA INCREASED 3 0.0006
313 PHLEBITIS 3 0.0006
314 ANKLE FRACTURE 9 0.0006
315 SKIN ULCER 15 0.0006
316 BLOOD MAGNESIUM DECREASED 5 0.0006
317 WRONG TECHNIQUE IN DRUG USAGE PROCESS 21 0.0006
318 FAILURE TO THRIVE 3 0.0006
319 WEIGHT FLUCTUATION 6 0.0006
320 THERAPEUTIC RESPONSE SHORTENED 19 0.0006
321 POST PROCEDURAL COMPLICATION 11 0.0006
322 APPLICATION SITE REACTION 4 0.0006
323 TUMOUR LYSIS SYNDROME 5 0.0006
324 PNEUMOTHORAX 9 0.0006
325 LUNG INFILTRATION 5 0.0006
326 PHARYNGOLARYNGEAL PAIN 3 0.0006
327 GASTROINTESTINAL MOTILITY DISORDER 3 0.0006
328 DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 4 0.0006
329 BRUXISM 3 0.0006
330 GRAFT VERSUS HOST DISEASE 4 0.0006
331 BLOOD POTASSIUM INCREASED 9 0.0006
332 GASTROENTERITIS VIRAL 10 0.0006
333 BIPOLAR DISORDER 6 0.0006
334 BACK INJURY 6 0.0006
335 LIQUID PRODUCT PHYSICAL ISSUE 4 0.0005
336 VENTRICULAR TACHYCARDIA 9 0.0005
337 DEAFNESS UNILATERAL 3 0.0005
338 CHOKING SENSATION 3 0.0005
339 PROSTATIC DISORDER 3 0.0005
340 SENSITIVE SKIN 4 0.0005
341 PRODUCT PHYSICAL CONSISTENCY ISSUE 3 0.0005
342 IRON DEFICIENCY ANAEMIA 5 0.0005
343 CEREBRAL DISORDER 4 0.0005
344 HEART RATE ABNORMAL 3 0.0005
345 OEDEMA 29 0.0005
346 ACUTE PULMONARY OEDEMA 3 0.0005
347 PHOTOPHOBIA 10 0.0005
348 SPUTUM DISCOLOURED 5 0.0005
349 OSTEOPENIA 8 0.0005
350 PANIC ATTACK 19 0.0005
351 FOOD ALLERGY 4 0.0005
352 LOW DENSITY LIPOPROTEIN INCREASED 4 0.0005
353 RETCHING 11 0.0005
354 ACCIDENTAL EXPOSURE TO PRODUCT 53 0.0005
355 VITAMIN D DEFICIENCY 5 0.0005
356 PULMONARY HAEMORRHAGE 4 0.0005
357 HYPOXIA 18 0.0005
358 SKIN DISORDER 17 0.0005
359 GLUCOSE TOLERANCE IMPAIRED 3 0.0005
360 LIGAMENT SPRAIN 5 0.0005
361 HEAD INJURY 16 0.0005
362 ODYNOPHAGIA 3 0.0005
363 OBESITY 8 0.0005
364 HAEMOPTYSIS 14 0.0005
365 PROTHROMBIN TIME PROLONGED 3 0.0005
366 DEVICE OCCLUSION 7 0.0005
367 FRUSTRATION TOLERANCE DECREASED 4 0.0005
368 NEURALGIA 12 0.0005
369 DERMATITIS ACNEIFORM 3 0.0005
370 SINUS TACHYCARDIA 7 0.0005
371 MIGRAINE 47 0.0005
372 BACK DISORDER 8 0.0005
373 TOOTH ABSCESS 5 0.0005
374 EUPHORIC MOOD 5 0.0005
375 ESCHERICHIA INFECTION 4 0.0005
376 RIB FRACTURE 10 0.0005
377 OROPHARYNGEAL PAIN 45 0.0005
378 STAPHYLOCOCCAL INFECTION 16 0.0005
379 TEMPERATURE INTOLERANCE 5 0.0005
380 HEART RATE INCREASED 48 0.0005
381 SPINAL COMPRESSION FRACTURE 4 0.0005
382 DYSPNOEA 273 0.0005
383 PNEUMONIA ASPIRATION 12 0.0005
384 FUNGAL INFECTION 16 0.0005
385 EOSINOPHIL COUNT INCREASED 4 0.0005
386 TINNITUS 22 0.0005
387 KNEE ARTHROPLASTY 10 0.0005
388 DRUG ADMINISTERED AT INAPPROPRIATE SITE 5 0.0005
389 FACIAL PARALYSIS 4 0.0005
390 BODY HEIGHT DECREASED 5 0.0005
391 HEREDITARY ANGIOEDEMA 5 0.0005
392 CARDIAC FLUTTER 3 0.0005
393 POOR QUALITY DRUG ADMINISTERED 3 0.0005
394 PULMONARY THROMBOSIS 5 0.0005
395 POLYP 3 0.0005
396 URINE OUTPUT DECREASED 4 0.0005
397 PRODUCT PREPARATION ISSUE 3 0.0005
398 POLLAKIURIA 19 0.0005
399 PHARYNGEAL OEDEMA 7 0.0005
400 BLOOD TRIGLYCERIDES INCREASED 8 0.0005
401 MUSCULOSKELETAL CHEST PAIN 7 0.0005
402 NERVE INJURY 5 0.0004
403 CYTOKINE RELEASE SYNDROME 9 0.0004
404 THIRST 8 0.0004
405 POST-TRAUMATIC STRESS DISORDER 3 0.0004
406 BREAST MASS 3 0.0004
407 EXTRA DOSE ADMINISTERED 18 0.0004
408 EYE INFECTION 5 0.0004
409 IMPAIRED DRIVING ABILITY 5 0.0004
410 MATERNAL EXPOSURE BEFORE PREGNANCY 3 0.0004
411 SCIATICA 7 0.0004
412 SCAB 5 0.0004
413 SKIN LESION 12 0.0004
414 NEPHROLITHIASIS 20 0.0004
415 INSOMNIA 116 0.0004
416 LYMPHOEDEMA 3 0.0004
417 GRAND MAL CONVULSION 4 0.0004
418 PERICARDIAL EFFUSION 10 0.0004
419 BRONCHITIS 32 0.0004
420 MUSCLE TIGHTNESS 7 0.0004
421 ORAL DISCOMFORT 6 0.0004
422 FORMICATION 3 0.0004
423 FEELING ABNORMAL 103 0.0004
424 EXTRASYSTOLES 3 0.0004
425 CARPAL TUNNEL SYNDROME 6 0.0004
426 DYSPEPSIA 42 0.0004
427 DISSEMINATED INTRAVASCULAR COAGULATION 6 0.0004
428 PAPULE 3 0.0004
429 EYE PAIN 24 0.0004
430 LACERATION 4 0.0004
431 LYMPHADENOPATHY 15 0.0004
432 PAIN IN JAW 12 0.0004
433 HAND FRACTURE 3 0.0004
434 THERAPY NON-RESPONDER 19 0.0004
435 JOINT INJURY 9 0.0004
436 DRY EYE 21 0.0004
437 METASTASIS 3 0.0004
438 HYPERLIPIDAEMIA 5 0.0004
439 PALPITATIONS 49 0.0004
440 GASTRITIS 11 0.0004
441 EYE PRURITUS 14 0.0004
442 ACUTE RESPIRATORY FAILURE 8 0.0004
443 SINUS BRADYCARDIA 4 0.0004
444 LOCALISED INFECTION 10 0.0004
445 HEMIPARESIS 7 0.0004
446 FAECES SOFT 3 0.0004
447 CLOSTRIDIUM DIFFICILE INFECTION 9 0.0004
448 FIBROMYALGIA 10 0.0004
449 MAJOR DEPRESSION 3 0.0004
450 BLOOD PRESSURE SYSTOLIC INCREASED 8 0.0004
451 COUGH 115 0.0004
452 GASTROOESOPHAGEAL REFLUX DISEASE 33 0.0004
453 BLOOD BILIRUBIN INCREASED 11 0.0004
454 VITREOUS FLOATERS 4 0.0004
455 BLINDNESS TRANSIENT 3 0.0004
456 CARDIOMEGALY 5 0.0004
457 PSYCHIATRIC SYMPTOM 3 0.0004
458 SMALL INTESTINAL OBSTRUCTION 5 0.0004
459 CARDIOMYOPATHY 6 0.0004
460 FLATULENCE 23 0.0004
461 SKIN HAEMORRHAGE 6 0.0004
462 FEELING DRUNK 3 0.0004
463 BLOOD POTASSIUM DECREASED 12 0.0004
464 BLOOD PRESSURE INCREASED 61 0.0004
465 DYSPNOEA EXERTIONAL 15 0.0004
466 EMPHYSEMA 4 0.0004
467 CHRONIC KIDNEY DISEASE 30 0.0004
468 DRY MOUTH 32 0.0004
469 ANXIETY 112 0.0004
470 DISCOMFORT 24 0.0004
471 HYPERSENSITIVITY 73 0.0004
472 SUBARACHNOID HAEMORRHAGE 4 0.0004
473 GALLBLADDER DISORDER 7 0.0004
474 INITIAL INSOMNIA 4 0.0004
475 CONGENITAL ANOMALY 3 0.0004
476 HYPOALBUMINAEMIA 3 0.0004
477 DRUG EFFECT INCOMPLETE 14 0.0004
478 APNOEA 3 0.0004
479 CONDITION AGGRAVATED 117 0.0004
480 BONE DISORDER 7 0.0004
481 UNEVALUABLE EVENT 29 0.0004
482 NODULE 5 0.0004
483 TRANSFUSION 4 0.0004
484 ANHEDONIA 10 0.0004
485 DYSURIA 14 0.0004
486 ATRIAL FIBRILLATION 37 0.0004
487 JOINT DISLOCATION 4 0.0004
488 OSTEOARTHRITIS 16 0.0004
489 CONJUNCTIVITIS 7 0.0004
490 GINGIVAL PAIN 3 0.0004
491 INFLUENZA 42 0.0004
492 EATING DISORDER 8 0.0004
493 PARAESTHESIA 59 0.0004
494 BLOOD PRESSURE FLUCTUATION 9 0.0004
495 MIOSIS 3 0.0004
496 QUALITY OF LIFE DECREASED 5 0.0004
497 MUSCLE DISORDER 3 0.0004
498 RENAL INJURY 11 0.0004
499 HEART RATE DECREASED 13 0.0004
500 PHARYNGITIS STREPTOCOCCAL 4 0.0004
501 DYSPHAGIA 35 0.0004
502 SKIN LACERATION 4 0.0004
503 ENCEPHALOPATHY 9 0.0004
504 GINGIVAL BLEEDING 5 0.0004
505 ABNORMAL FAECES 3 0.0004
506 INTENTIONAL PRODUCT USE ISSUE 32 0.0004
507 LETHARGY 21 0.0004
508 PERIPHERAL COLDNESS 5 0.0004
509 CENTRAL NERVOUS SYSTEM LESION 5 0.0004
510 GASTROINTESTINAL PAIN 4 0.0004
511 MELAENA 8 0.0004
512 CORONARY ARTERY DISEASE 11 0.0004
513 DIVERTICULITIS 10 0.0004
514 VENTRICULAR FIBRILLATION 4 0.0004
515 COAGULOPATHY 6 0.0004
516 FEELING COLD 10 0.0004
517 SURGERY 21 0.0004
518 NECK PAIN 20 0.0004
519 DEPRESSION 81 0.0004
520 HEART RATE IRREGULAR 8 0.0004
521 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 6 0.0004
522 DISORIENTATION 14 0.0004
523 DISTURBANCE IN ATTENTION 19 0.0004
524 HYPOPHAGIA 9 0.0004
525 BRONCHOSPASM 5 0.0004
526 MICTURITION URGENCY 4 0.0003
527 PSEUDOMONAS INFECTION 3 0.0003
528 GASTRIC DISORDER 12 0.0003
529 MUSCULOSKELETAL DISCOMFORT 6 0.0003
530 HYPOACUSIS 15 0.0003
531 IMPAIRED QUALITY OF LIFE 5 0.0003
532 SOMNOLENCE 70 0.0003
533 EYE IRRITATION 20 0.0003
534 HAEMATOMA 9 0.0003
535 NASOPHARYNGITIS 64 0.0003
536 PARAESTHESIA ORAL 5 0.0003
537 PHARMACEUTICAL PRODUCT COMPLAINT 9 0.0003
538 DYSARTHRIA 13 0.0003
539 LOCAL SWELLING 6 0.0003
540 SPEECH DISORDER 18 0.0003
541 NAIL DISORDER 3 0.0003
542 ERYTHEMA 70 0.0003
543 ASCITES 10 0.0003
544 PNEUMONIA 110 0.0003
545 HEADACHE 213 0.0003
546 PRODUCT QUALITY ISSUE 46 0.0003
547 SWELLING FACE 22 0.0003
548 DRUG EFFECT LESS THAN EXPECTED 5 0.0003
549 ASTHMA 38 0.0003
550 PULMONARY MASS 5 0.0003
551 HEAVY MENSTRUAL BLEEDING 3 0.0003
552 OSTEOMYELITIS 6 0.0003
553 LIP DRY 3 0.0003
554 TREATMENT NONCOMPLIANCE 18 0.0003
555 HIDRADENITIS 3 0.0003
556 EXOSTOSIS 3 0.0003
557 NO THERAPEUTIC RESPONSE 4 0.0003
558 IMPAIRED WORK ABILITY 7 0.0003
559 RESPIRATORY DISTRESS 9 0.0003
560 INCREASED TENDENCY TO BRUISE 3 0.0003
561 TRANSIENT ISCHAEMIC ATTACK 11 0.0003
562 ABDOMINAL DISTENSION 34 0.0003
563 NERVOUSNESS 17 0.0003
564 DYSPHONIA 19 0.0003
565 HYPERCALCAEMIA 4 0.0003
566 LIMB DISCOMFORT 10 0.0003
567 TENDONITIS 5 0.0003
568 DEHYDRATION 43 0.0003
569 HEPATIC STEATOSIS 6 0.0003
570 WOUND 9 0.0003
571 BLOOD CHOLESTEROL INCREASED 15 0.0003
572 INTERVERTEBRAL DISC PROTRUSION 7 0.0003
573 SWOLLEN TONGUE 10 0.0003
574 OEDEMA PERIPHERAL 39 0.0003
575 ARTERIOSCLEROSIS 3 0.0003
576 BRAIN OEDEMA 4 0.0003
577 OCULAR HYPERAEMIA 15 0.0003
578 BLOOD PRESSURE DECREASED 21 0.0003
579 INTENTIONAL DOSE OMISSION 9 0.0003
580 DISEASE RECURRENCE 15 0.0003
581 COVID-19 55 0.0003
582 ABSCESS 5 0.0003
583 AGITATION 23 0.0003
584 INJURY 22 0.0003
585 PULMONARY OEDEMA 14 0.0003
586 CHEST DISCOMFORT 32 0.0003
587 MYDRIASIS 4 0.0003
588 HYPERTENSION 66 0.0003
589 GLAUCOMA 6 0.0003
590 ROAD TRAFFIC ACCIDENT 13 0.0003
591 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 56 0.0003
592 URTICARIA 52 0.0003
593 HERNIA 6 0.0003
594 ERUCTATION 6 0.0003
595 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 17 0.0003
596 LIVER FUNCTION TEST ABNORMAL 9 0.0003
597 DIZZINESS POSTURAL 3 0.0003
598 CHEST PAIN 57 0.0003
599 CONSTIPATION 67 0.0003
600 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 16 0.0003
601 DECREASED IMMUNE RESPONSIVENESS 3 0.0003
602 HEPATOMEGALY 3 0.0003
603 WHITE BLOOD CELL COUNT DECREASED 33 0.0003
604 IMMUNE SYSTEM DISORDER 4 0.0003
605 OXYGEN SATURATION DECREASED 17 0.0003
606 BLOOD PRESSURE ABNORMAL 6 0.0003
607 ADVERSE REACTION 4 0.0003
608 UNDERDOSE 22 0.0003
609 PSYCHOMOTOR HYPERACTIVITY 5 0.0003
610 WEIGHT DECREASED 84 0.0003
611 RESPIRATORY DISORDER 9 0.0003
612 VIRAL INFECTION 10 0.0003
613 SPINAL FRACTURE 6 0.0003
614 MUSCULAR WEAKNESS 34 0.0003
615 BLOOD UREA INCREASED 5 0.0003
616 SLEEP DISORDER 21 0.0003
617 CANDIDA INFECTION 5 0.0003
618 PLEURAL EFFUSION 18 0.0003
619 HYPERHIDROSIS 38 0.0003
620 FLUID RETENTION 15 0.0003
621 HYPOAESTHESIA 44 0.0003
622 DRUG ADMINISTRATION ERROR 9 0.0003
623 TACHYCARDIA 26 0.0003
624 HAEMOGLOBIN DECREASED 30 0.0003
625 OSTEOPOROSIS 12 0.0003
626 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 14 0.0003
627 POOR VENOUS ACCESS 3 0.0003
628 ABNORMAL DREAMS 8 0.0003
629 HYPERBILIRUBINAEMIA 3 0.0003
630 TOOTH LOSS 6 0.0003
631 SWELLING 27 0.0003
632 MENTAL STATUS CHANGES 8 0.0003
633 PULMONARY HYPERTENSION 6 0.0003
634 URINARY TRACT INFECTION 49 0.0003
635 HUNGER 4 0.0003
636 INTENTIONAL DRUG MISUSE 6 0.0003
637 RASH MACULAR 10 0.0003
638 DRUG INEFFECTIVE 376 0.0003
639 COLD SWEAT 5 0.0003
640 BLINDNESS UNILATERAL 4 0.0003
641 TREMOR 47 0.0003
642 CLOSTRIDIUM DIFFICILE COLITIS 3 0.0003
643 LYMPHOCYTE COUNT DECREASED 5 0.0003
644 DIZZINESS 141 0.0003
645 CYSTITIS 9 0.0003
646 HEAD DISCOMFORT 5 0.0003
647 HYPOTHYROIDISM 9 0.0003
648 ILLNESS 29 0.0003
649 PRURITUS 108 0.0003
650 STOMATITIS 17 0.0003
651 MOVEMENT DISORDER 9 0.0003
652 ISCHAEMIC STROKE 5 0.0003
653 IRRITABLE BOWEL SYNDROME 6 0.0003
654 NIGHT SWEATS 9 0.0003
655 HYPERSOMNIA 8 0.0003
656 GOUT 5 0.0003
657 HOT FLUSH 21 0.0003
658 HERPES ZOSTER 16 0.0003
659 GLYCOSYLATED HAEMOGLOBIN INCREASED 7 0.0003
660 FALL 92 0.0003
661 PULMONARY ARTERIAL HYPERTENSION 4 0.0003
662 COMPLICATION ASSOCIATED WITH DEVICE 4 0.0003
663 FLUSHING 28 0.0003
664 CRYING 10 0.0003
665 OESOPHAGITIS 3 0.0003
666 RESPIRATORY FAILURE 20 0.0003
667 INTENTIONAL PRODUCT MISUSE 24 0.0003
668 RESTLESSNESS 10 0.0003
669 SKIN EXFOLIATION 23 0.0003
670 FOOT DEFORMITY 3 0.0003
671 CONTUSION 26 0.0003
672 URINARY RETENTION 9 0.0003
673 GLOSSODYNIA 6 0.0003
674 HAEMORRHAGE 28 0.0003
675 MIDDLE INSOMNIA 5 0.0003
676 OCULAR DISCOMFORT 3 0.0003
677 BLISTER 15 0.0003
678 BLOOD CALCIUM DECREASED 3 0.0003
679 HYPOAESTHESIA ORAL 4 0.0003
680 DRUG EXPOSURE DURING PREGNANCY 9 0.0003
681 HAEMATURIA 9 0.0003
682 ABDOMINAL DISCOMFORT 44 0.0003
683 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 53 0.0003
684 CARDIAC FAILURE CONGESTIVE 21 0.0003
685 AMNESIA 17 0.0003
686 FEELING HOT 16 0.0003
687 MUSCLE TWITCHING 6 0.0003
688 SEPSIS 29 0.0003
689 HYPOTENSION 52 0.0003
690 PRODUCT DOSE OMISSION ISSUE 76 0.0003
691 ELECTROLYTE IMBALANCE 3 0.0003
692 CELLULITIS 13 0.0003
693 LIMB INJURY 7 0.0003
694 BASAL CELL CARCINOMA 4 0.0003
695 HAEMORRHOIDS 5 0.0003
696 FEBRILE NEUTROPENIA 17 0.0003
697 BONE PAIN 15 0.0003
698 RECTAL HAEMORRHAGE 11 0.0003
699 DIARRHOEA 165 0.0003
700 CYANOSIS 4 0.0003
701 ARTHRITIS 20 0.0003
702 ARRHYTHMIA 12 0.0003
703 THERAPY CESSATION 13 0.0003
704 ATAXIA 3 0.0003
705 PROCEDURAL PAIN 7 0.0003
706 PAIN 155 0.0003
707 HALLUCINATION 19 0.0003
708 ACCIDENT 3 0.0003
709 ASTHENIA 94 0.0002
710 PREGNANCY 5 0.0002
711 SENSORY DISTURBANCE 4 0.0002
712 HIP FRACTURE 8 0.0002
713 ECZEMA 13 0.0002
714 ACUTE KIDNEY INJURY 38 0.0002
715 MUSCULOSKELETAL PAIN 13 0.0002
716 FATIGUE 193 0.0002
717 BURSITIS 3 0.0002
718 ADRENAL INSUFFICIENCY 3 0.0002
719 TASTE DISORDER 5 0.0002
720 PRODUCT USE IN UNAPPROVED INDICATION 61 0.0002
721 INTERNATIONAL NORMALISED RATIO INCREASED 7 0.0002
722 BACK PAIN 57 0.0002
723 BRADYCARDIA 13 0.0002
724 LUNG DISORDER 12 0.0002
725 RED BLOOD CELL COUNT DECREASED 7 0.0002
726 INJECTION SITE URTICARIA 6 0.0002
727 GLOMERULAR FILTRATION RATE DECREASED 3 0.0002
728 METASTASES TO BONE 4 0.0002
729 IMPAIRED HEALING 8 0.0002
730 BALANCE DISORDER 21 0.0002
731 GENERALISED TONIC-CLONIC SEIZURE 4 0.0002
732 CYST 3 0.0002
733 ILEUS 3 0.0002
734 PERIPHERAL SWELLING 37 0.0002
735 SKIN IRRITATION 11 0.0002
736 NAUSEA 190 0.0002
737 SYNCOPE 24 0.0002
738 POISONING 3 0.0002
739 INTESTINAL OBSTRUCTION 9 0.0002
740 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 8 0.0002
741 MUSCLE ATROPHY 3 0.0002
742 WHEEZING 14 0.0002
743 INJECTION SITE IRRITATION 3 0.0002
744 CARDIAC DISORDER 22 0.0002
745 CATARACT 14 0.0002
746 MUSCLE SPASMS 43 0.0002
747 ERECTILE DYSFUNCTION 6 0.0002
748 SCAR 4 0.0002
749 LIVER FUNCTION TEST INCREASED 5 0.0002
750 INFLAMMATION 12 0.0002
751 UNRESPONSIVE TO STIMULI 6 0.0002
752 VERTIGO 14 0.0002
753 PRODUCT PRESCRIBING ISSUE 5 0.0002
754 CONFUSIONAL STATE 37 0.0002
755 ABDOMINAL PAIN UPPER 47 0.0002
756 BEDRIDDEN 3 0.0002
757 INFECTION 33 0.0002
758 ANKYLOSING SPONDYLITIS 3 0.0002
759 RENAL FAILURE 30 0.0002
760 VISION BLURRED 31 0.0002
761 PLATELET COUNT DECREASED 24 0.0002
762 SEIZURE 26 0.0002
763 TOOTH DISORDER 5 0.0002
764 ACNE 17 0.0002
765 WEIGHT INCREASED 50 0.0002
766 THERAPEUTIC PRODUCT EFFECT DECREASED 10 0.0002
767 FEAR 6 0.0002
768 PAIN OF SKIN 6 0.0002
769 CHROMATURIA 5 0.0002
770 BLINDNESS 9 0.0002
771 PAIN IN EXTREMITY 65 0.0002
772 RESTLESS LEGS SYNDROME 4 0.0002
773 MOOD SWINGS 7 0.0002
774 INFLUENZA LIKE ILLNESS 18 0.0002
775 LOSS OF CONSCIOUSNESS 28 0.0002
776 MEMORY IMPAIRMENT 30 0.0002
777 ANAPHYLACTIC REACTION 12 0.0002
778 HYPOKALAEMIA 10 0.0002
779 HYPOMAGNESAEMIA 3 0.0002
780 DECREASED APPETITE 50 0.0002
781 BLOOD CREATININE INCREASED 14 0.0002
782 BACTERIAL INFECTION 4 0.0002
783 BLOOD TEST ABNORMAL 3 0.0002
784 CHOLELITHIASIS 7 0.0002
785 TUBULOINTERSTITIAL NEPHRITIS 4 0.0002
786 MATERNAL EXPOSURE DURING PREGNANCY 19 0.0002
787 BLOOD SODIUM DECREASED 4 0.0002
788 PRODUCT DOSE OMISSION IN ERROR 6 0.0002
789 MULTIPLE ORGAN DYSFUNCTION SYNDROME 6 0.0002
790 DIALYSIS 3 0.0002
791 PULMONARY EMBOLISM 20 0.0002
792 NEUROPATHY PERIPHERAL 20 0.0002
793 MUSCULOSKELETAL DISORDER 4 0.0002
794 THERAPY INTERRUPTED 15 0.0002
795 CARDIOGENIC SHOCK 3 0.0002
796 TYPE 2 DIABETES MELLITUS 7 0.0002
797 HYPERTHYROIDISM 3 0.0002
798 MENTAL DISORDER 9 0.0002
799 PRESCRIBED OVERDOSE 4 0.0002
800 CEREBROVASCULAR ACCIDENT 35 0.0002
801 EMOTIONAL DISTRESS 25 0.0002
802 MENTAL IMPAIRMENT 5 0.0002
803 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 6 0.0002
804 SKIN FISSURES 4 0.0002
805 KIDNEY INFECTION 4 0.0002
806 RASH PRURITIC 11 0.0002
807 ABASIA 5 0.0002
808 NIGHTMARE 7 0.0002
809 BLOOD ALKALINE PHOSPHATASE INCREASED 5 0.0002
810 PYREXIA 69 0.0002
811 HEPATIC FAILURE 6 0.0002
812 THROMBOSIS 16 0.0002
813 JOINT SWELLING 24 0.0002
814 FULL BLOOD COUNT DECREASED 4 0.0002
815 LOWER RESPIRATORY TRACT INFECTION 9 0.0002
816 BLOOD COUNT ABNORMAL 3 0.0002
817 PRODUCT COMPLAINT 5 0.0002
818 PANCYTOPENIA 11 0.0002
819 DIABETES MELLITUS 15 0.0002
820 BODY TEMPERATURE INCREASED 4 0.0002
821 SKIN DISCOLOURATION 9 0.0002
822 DEVICE RELATED INFECTION 3 0.0002
823 GAIT DISTURBANCE 37 0.0002
824 EJECTION FRACTION DECREASED 3 0.0002
825 INCORRECT DOSE ADMINISTERED 44 0.0002
826 ARTHRALGIA 80 0.0002
827 HYPERGLYCAEMIA 7 0.0002
828 DEAFNESS 5 0.0002
829 WITHDRAWAL SYNDROME 8 0.0002
830 DEPRESSED MOOD 10 0.0002
831 METABOLIC ACIDOSIS 6 0.0002
832 DRY SKIN 25 0.0002
833 VOMITING 88 0.0002
834 RASH 81 0.0002
835 SKIN CANCER 4 0.0002
836 ABDOMINAL PAIN 43 0.0002
837 ALTERED STATE OF CONSCIOUSNESS 4 0.0002
838 FAECES DISCOLOURED 4 0.0002
839 PALLOR 5 0.0002
840 MULTIPLE FRACTURES 3 0.0002
841 THERAPEUTIC RESPONSE DECREASED 11 0.0002
842 INFUSION RELATED REACTION 12 0.0002
843 LIP SWELLING 6 0.0002
844 MALAISE 79 0.0002
845 MEDICATION ERROR 10 0.0002
846 RASH MACULO-PAPULAR 4 0.0002
847 NEOPLASM MALIGNANT 12 0.0002
848 GAIT INABILITY 6 0.0002
849 DEMENTIA 5 0.0002
850 GASTROINTESTINAL DISORDER 16 0.0002
851 PERICARDITIS 3 0.0002
852 DEVICE ISSUE 16 0.0002
853 FACE OEDEMA 3 0.0002
854 ANGER 6 0.0002
855 OVERDOSE 38 0.0002
856 ANGINA PECTORIS 5 0.0002
857 PARANOIA 3 0.0002
858 NEOPLASM PROGRESSION 6 0.0002
859 ORTHOSTATIC HYPOTENSION 3 0.0002
860 NEUROTOXICITY 3 0.0002
861 METASTASES TO LIVER 3 0.0002
862 ACUTE RESPIRATORY DISTRESS SYNDROME 3 0.0002
863 ACUTE MYOCARDIAL INFARCTION 5 0.0002
864 ASPARTATE AMINOTRANSFERASE INCREASED 9 0.0002
865 URINARY INCONTINENCE 5 0.0002
866 APHASIA 5 0.0002
867 C-REACTIVE PROTEIN INCREASED 6 0.0002
868 MYALGIA 28 0.0002
869 FEMUR FRACTURE 5 0.0002
870 EYE SWELLING 6 0.0002
871 BONE DENSITY DECREASED 5 0.0002
872 HYPOCALCAEMIA 3 0.0002
873 COLITIS 6 0.0002
874 BLOOD URINE PRESENT 3 0.0002
875 LIVER DISORDER 7 0.0002
876 CARDIAC ARREST 13 0.0002
877 INCREASED APPETITE 3 0.0002
878 DEVICE MALFUNCTION 11 0.0002
879 PRODUCT SUBSTITUTION ISSUE 9 0.0002
880 CHOLESTASIS 3 0.0002
881 GASTROINTESTINAL HAEMORRHAGE 13 0.0002
882 MYOCARDIAL INFARCTION 27 0.0002
883 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 11 0.0002
884 DIPLOPIA 4 0.0002
885 BLOOD GLUCOSE INCREASED 29 0.0002
886 DEEP VEIN THROMBOSIS 10 0.0002
887 SKIN BURNING SENSATION 11 0.0002
888 VISUAL IMPAIRMENT 19 0.0002
889 PRODUCT DOSE OMISSION 10 0.0002
890 OFF LABEL USE 134 0.0002
891 SEDATION 4 0.0002
892 OSTEONECROSIS 5 0.0002
893 ANAEMIA 29 0.0002
894 DERMATITIS ATOPIC 8 0.0002
895 ACTIVITIES OF DAILY LIVING IMPAIRED 3 0.0002
896 COGNITIVE DISORDER 7 0.0001
897 INJECTION SITE PRURITUS 10 0.0001
898 FEEDING DISORDER 3 0.0001
899 PSORIATIC ARTHROPATHY 6 0.0001
900 PNEUMONITIS 4 0.0001
901 ALANINE AMINOTRANSFERASE INCREASED 9 0.0001
902 RASH ERYTHEMATOUS 7 0.0001
903 DEVICE DELIVERY SYSTEM ISSUE 4 0.0001
904 PSORIASIS 19 0.0001
905 RESPIRATORY ARREST 4 0.0001
906 CHILLS 17 0.0001
907 DRUG INTERACTION 23 0.0001
908 ARTHROPATHY 8 0.0001
909 DERMATITIS 3 0.0001
910 RENAL IMPAIRMENT 12 0.0001
911 MOUTH ULCERATION 3 0.0001
912 HALLUCINATION, VISUAL 3 0.0001
913 HYPONATRAEMIA 8 0.0001
914 CONVULSION 8 0.0001
915 INCORRECT ROUTE OF DRUG ADMINISTRATION 5 0.0001
916 DRUG DOSE OMISSION 23 0.0001
917 SEPTIC SHOCK 6 0.0001
918 INJECTION SITE BRUISING 11 0.0001
919 NEEDLE ISSUE 4 0.0001
920 ACCIDENTAL OVERDOSE 5 0.0001
921 IRRITABILITY 8 0.0001
922 ILL-DEFINED DISORDER 8 0.0001
923 SUICIDAL IDEATION 12 0.0001
924 ADVERSE EVENT 12 0.0001
925 RENAL DISORDER 6 0.0001
926 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 3 0.0001
927 ABNORMAL BEHAVIOUR 5 0.0001
928 CARDIAC FAILURE 10 0.0001
929 DRUG INTOLERANCE 12 0.0001
930 DYSKINESIA 5 0.0001
931 ADVERSE DRUG REACTION 11 0.0001
932 OSTEONECROSIS OF JAW 3 0.0001
933 DRUG ABUSE 10 0.0001
934 ABDOMINAL PAIN LOWER 3 0.0001
935 HAEMATEMESIS 3 0.0001
936 CARDIOVASCULAR DISORDER 3 0.0001
937 RENAL FAILURE ACUTE 5 0.0001
938 NEUTROPENIA 16 0.0001
939 INJECTION SITE SWELLING 9 0.0001
940 ALOPECIA 23 0.0001
941 ANAPHYLACTIC SHOCK 3 0.0001
942 RASH GENERALISED 3 0.0001
943 DELIRIUM 4 0.0001
944 DEVICE DISLOCATION 5 0.0001
945 INCORRECT DOSE ADMINISTERED BY DEVICE 3 0.0001
946 INJECTION SITE PAIN 35 0.0001
947 ANGIOEDEMA 5 0.0001
948 JAUNDICE 3 0.0001
949 FREQUENT BOWEL MOVEMENTS 3 0.0001
950 INJECTION SITE MASS 4 0.0001
951 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 5 0.0001
952 DYSSTASIA 3 0.0001
953 HEPATIC ENZYME INCREASED 7 0.0001
954 PLASMA CELL MYELOMA 4 0.0001
955 DISEASE PROGRESSION 12 0.0001
956 CONTRAINDICATED PRODUCT ADMINISTERED 3 0.0001
957 MOBILITY DECREASED 7 0.0001
958 EMOTIONAL DISORDER 3 0.0001
959 RHEUMATOID ARTHRITIS 11 0.0001
960 EXPOSURE DURING PREGNANCY 6 0.0001
961 CARDIO-RESPIRATORY ARREST 4 0.0001
962 DEVICE LEAKAGE 4 0.0001
963 EYE DISORDER 3 0.0001
964 THROMBOCYTOPENIA 10 0.0001
965 INJECTION SITE ERYTHEMA 11 0.0001
966 HYPERKALAEMIA 3 0.0001
967 COMA 4 0.0001
968 HYPOGLYCAEMIA 4 0.0001
969 AGGRESSION 4 0.0001
970 DEATH 65 0.0001
971 INJECTION SITE HAEMORRHAGE 6 0.0001
972 ABORTION SPONTANEOUS 3 0.0001
973 FOETAL EXPOSURE DURING PREGNANCY 6 0.0001
974 INJECTION SITE REACTION 5 0.0001
975 HAEMATOCHEZIA 4 0.0001
976 PRODUCT STORAGE ERROR 6 0.0001
977 MUSCULOSKELETAL STIFFNESS 6 0.0001
978 MALIGNANT NEOPLASM PROGRESSION 7 0.0001
979 HOSPITALISATION 10 0.0001
980 BREAST CANCER 6 0.0001
981 MULTIPLE SCLEROSIS 3 0.0001
982 BLOOD GLUCOSE DECREASED 3 0.0001
983 INTERSTITIAL LUNG DISEASE 3 0.0001
984 GENERAL PHYSICAL HEALTH DETERIORATION 7 0.0001
985 MULTIPLE SCLEROSIS RELAPSE 4 0.0001
986 PANCREATITIS 3 0.0001
987 DEVICE EXPULSION 3 0.0000
988 DRUG WITHDRAWAL SYNDROME 4 0.0000
989 DRUG DOSE OMISSION BY DEVICE 3 0.0000
990 PROSTATE CANCER 3 0.0000
991 TOXICITY TO VARIOUS AGENTS 6 0.0000
992 NO ADVERSE EVENT 4 0.0000